RecruitingPhase 3NCT03593759

Cardiac Sarcoidosis Randomized Trial

Studying Sarcoidosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Ottawa Heart Institute Research Corporation
Principal Investigator: David H Birnie, MD
Ottawa Heart Institute Research Corporation
Intervention: Prednisone or Prednisolone(drug)
Enrollment: 194 target
Eligibility: 18 years · All sexes
Timeline: 2019 – 2025

Study locations (30)

Yale-New Haven Hospital, New Haven, Connecticut, United States
Tufts Medical Center, Boston, Massachusetts, United States
University of Michigan-Michigan Medicine Cardiovascular Center, Ann Arbor, Michigan, United States
University of Minnesota, Minneota, Minnesota, United States
Montefiore Medical Center, New York, New York, United States
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
University of Utah, Salt Lake City, Utah, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada
St. Paul's Hospital, Vancouver, British Columbia, Canada
Eastern Health Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada
QE II Health Sciences Centre, Halifax, Nova Scotia, Canada
St. Joseph's Healthcare Centre, Hamilton, Ontario, Canada
London Health Sciences Centre, London, Ontario, Canada
+15 more locations on ClinicalTrials.gov

Collaborators

Canadian Institutes of Health Research (CIHR)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03593759 on ClinicalTrials.gov

Other trials for Sarcoidosis

Additional recruiting or active studies for the same condition.

See all trials for Sarcoidosis →

← Back to all trials